Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 810-811 |
| Number of pages | 2 |
| Journal | Clinical Infectious Diseases |
| Volume | 66 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 10 Feb 2018 |
Cite this
}
Dose Suggestions for Intravenous Colistin in Pediatric Patients : Caution Required. / Nation, Roger L.
In: Clinical Infectious Diseases, Vol. 66, No. 5, 10.02.2018, p. 810-811.Research output: Contribution to journal › Letter › Other
TY - JOUR
T1 - Dose Suggestions for Intravenous Colistin in Pediatric Patients
T2 - Caution Required
AU - Nation, Roger L.
PY - 2018/2/10
Y1 - 2018/2/10
N2 - To the Editor—Mesini et al reported plasma concentrations of colistin in 7 pediatric patients (aged 46 days to 13 years) who were receiving intravenously the inactive prodrug colistimethate; across all patients, plasma colistin concentrations were measured on 13 occasions [1]. That report has been the subject of critical appraisal by Magréault et al [2], who expressed substantial concerns about the magnitude of the plasma colistin concentrations reported and the pharmacokinetic analysis conducted by Mesini and coworkers. I agree with Magréault et al and amplify their comments. I have very substantial concerns about the dosing recommendations implicitly presented in the report of Mesini and coworkers.
AB - To the Editor—Mesini et al reported plasma concentrations of colistin in 7 pediatric patients (aged 46 days to 13 years) who were receiving intravenously the inactive prodrug colistimethate; across all patients, plasma colistin concentrations were measured on 13 occasions [1]. That report has been the subject of critical appraisal by Magréault et al [2], who expressed substantial concerns about the magnitude of the plasma colistin concentrations reported and the pharmacokinetic analysis conducted by Mesini and coworkers. I agree with Magréault et al and amplify their comments. I have very substantial concerns about the dosing recommendations implicitly presented in the report of Mesini and coworkers.
UR - http://www.scopus.com/inward/record.url?scp=85051675011&partnerID=8YFLogxK
U2 - 10.1093/cid/cix1048
DO - 10.1093/cid/cix1048
M3 - Letter
VL - 66
SP - 810
EP - 811
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 5
ER -